Randomised double blind trial of safety of anti-tumour necrosis factor (anti-TNF) chimeric monoclonal antibody (infliximab) in combination with methatrexate compared to methatrexate alone in patients with rheumatoid arthritis on standard disease modifying anti-rheumatic drugs

http://isrctn.org/> ◽

10.1186/isrctn51200229 ◽

2013 ◽

Author(s):

Simon Till

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Chimeric Monoclonal Antibody ◽

Disease Modifying ◽

Necrosis Factor

Download Full-text

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

10.1016/s0140-6736(94)90628-9 ◽

1994 ◽

Vol 344 (8930) ◽

pp. 1105-1110 ◽

Cited By ~ 1098

Author(s):

M.J Elliott ◽

R.N Maini ◽

M Feldmann ◽

J.R Kalden ◽

C Antoni ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Α ◽

Double Blind ◽

Chimeric Monoclonal Antibody ◽

Blind Comparison ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Classic Papers in Rheumatology ◽

10.3109/9780203214237-215 ◽

2001 ◽

pp. 438-439

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Alpha ◽

Double Blind ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Blind Comparison ◽

Necrosis Factor

Download Full-text

FRI0060 Successful treatment of active rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor (infliximab): an open study

10.1136/annrheumdis-2001.1189 ◽

2001 ◽

Author(s):

KA Boki ◽

VA Vassiliou ◽

G Linardaki ◽

HM Moutsopoulos

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumour Necrosis Factor ◽

Successful Treatment ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Chimeric Monoclonal Antibody ◽

Necrosis Factor

Download Full-text

Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus

Rheumatology ◽

10.1093/rheumatology/key076 ◽

2018 ◽

Vol 57 (Supplement_7) ◽

pp. vii32-vii41

Author(s):

Alessandra Bortoluzzi ◽

Guido Valesini ◽

Salvatore D’Angelo ◽

Bruno Frediani ◽

Laura Bazzichi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Expert Consensus ◽

Tumour Necrosis Factor Inhibitors ◽

Disease Modifying ◽

Necrosis Factor

Download Full-text

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2011-200956 ◽

2012 ◽

Vol 71 (10) ◽

pp. 1671-1679 ◽

Author(s):

Josef S Smolen ◽

Jonathan Kay ◽

Robert B M Landewé ◽

Eric L Matteson ◽

Norman Gaylis ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Previous Experience ◽

Double Blind ◽

Double Blind Placebo ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Download Full-text

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

Annals of the Rheumatic Diseases ◽

10.1136/ard.2010.132134 ◽

2010 ◽

Vol 70 (2) ◽

pp. 266-271 ◽

Author(s):

C. Salliot ◽

A. Finckh ◽

W. Katchamart ◽

Y. Lu ◽

Y. Sun ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Meta Analysis ◽

Inadequate Response ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Disease Modifying ◽

Indirect Comparisons ◽

Necrosis Factor

Download Full-text

Efficacy and safety of the fully human anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

Annals of the Rheumatic Diseases ◽

10.1136/ard.2003.009563 ◽

2003 ◽

Vol 62 (12) ◽

pp. 1168-1177 ◽

Author(s):

L B A van de Putte

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumour Necrosis Factor ◽

Phase Ii ◽

Tumour Necrosis ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718257967.793494565 ◽

2014 ◽

Author(s):

Christian Jorgensen ◽

Yves-Marie Pers

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

http://isrctn.org/> ◽

10.1186/isrctn37438295 ◽

2012 ◽

Author(s):

David L Scott

Keyword(s):

Rheumatoid Arthritis ◽

Randomised Controlled Trial ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Intensive Therapy ◽

Established Rheumatoid Arthritis ◽

Disease Modifying ◽

Randomised Controlled ◽

Necrosis Factor

Download Full-text

CDP571, a humanised monoclonal antibody to tumour necrosis factor , for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

Gut ◽

10.1136/gut.2003.035253 ◽

2004 ◽

Vol 53 (10) ◽

pp. 1485-1493 ◽

Author(s):

W J Sandborn

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text